Chugai's HEMLIBRA® Approved by European Commission in Hemophilia A with Inhibitors
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche has received regulatory approval from the European Commission for HEMLIBRA ® (emicizumab) for routine prophylaxis of bleeding episodes in people with hemophilia A with factor VIII inhibitors.
“Following the US approval, we are very proud of the approval to deliver the first-in-class product HEMLIBRA to people with hemophilia A with inhibitors in the EU as well,” said Chugai’s President & COO, Tatsuro Kosaka. “By having HEMLIBRA – an additional Chugai originated medicine to the existing product lineup currently marketed in the EU, such as RoACTEMRA ® and ALECENSA ® , we are continuously committed to resolve unmet medical needs for patients in the EU jointly with Roche.”
This approval is based on the two pivotal studies for hemophilia A with inhibitors: the results of HAVEN1 study (NCT02622321) for adolescents and adults, and the interim analysis of HAVEN2 study (NCT02795767) in children.
HEMLIBRA is a bispecific monoclonal antibody, which was developed using Chugai’s proprietary antibody engineering technologies. The drug is designed to bind factor IXa and factor X. In doing so, HEMLIBRA provides the cofactor function of factor VIII in people with hemophilia A, who either lack or have impaired coagulation function of factor VIII1, 2). In November 2017, the drug (US product name: HEMLIBRA®; Genentech) was approved by the U.S. Food and Drug Administration and was marketed for “routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.” In Japan, HEMLIBRA obtained an orphan drug designation in August 2016 from the Ministry of Health, Labour and Welfare for the prevention and reduction of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) who developed inhibitors to factor VIII, followed by an application for regulatory approval filed in July 2017.
About the results of HAVEN1 study and HAVEN2 study
Press release issued on June 26, 2017
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals, and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totaled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.
Trademarks used or mentioned in this release are protected by law.
1) Kitazawa, et al. Nature Medicine 2012; 18(10): 1570
2) Sampei, et al. PLoS ONE 2013; 8: e57479
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Interxion Announces Direct Connectivity to Google Cloud Platform across Its European Footprint14.8.2018 11:00 | Tiedote
INTERXION HOLDING NV (NYSE: INXN), a leading provider of carrier and cloud-neutral colocation data centre services in Europe, today announced that dedicated access to Google Cloud Platform (GCP) is now available across its European footprint through Cloud Connect, Interxion’s multi-cloud interconnection platform. With Google Cloud deploying its Cloud Interconnect points of presence (PoPs) in Interxion’s Paris, Marseille, Frankfurt and Stockholm data centres, customers can now directly connect to Google Cloud Platform from these locations. Moreover, because Interxion is a partner of Google Cloud’s newly launched Partner Interconnect service, customers can also connect from any of Interxion’s data centres across Europe via Cloud Connect. Customers using this service benefit from fully redundant, instant access to GCP from multiple metropolitan areas, ensuring a 99.99% availability SLA without the complexity and costs of having to build a networking solution themselves. “We are seeing str
Lumileds Wins Jury Verdict of Liability for Intellectual Property Theft Against Elec-Tech International Co., Ltd., Donglei Wang, and Gangyi Chen14.8.2018 01:45 | Tiedote
On August 10, 2018, a jury of six men and six women rendered a verdict in favor of one the world’s leading LED companies, Lumileds LLC, based in San Jose, finding that a Chinese competitor stole trade secrets related to Lumileds core technology for making high power LEDs used in flash phones, automotive headlights, and general illumination. The case, Lumileds LLC v. Elec-Tech International Co., Ltd., Donglei “Tony” Wang, and Gangyi Chen, Superior Court of the State of California, County of Santa Clara, found the defendants liable for damages in intellectual property theft. The jury awarded Lumileds $66 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180813005694/en/ Mark Adams, Chief Executive Officer at Lumileds Inc. (Photo: Business Wire) The jury concluded that ETI, Wang and Chen misappropriated Lumileds trade secrets, took them to China, and used them to develop ETI’s LED technology. The award of $66 million is t
Seoul Semiconductor’s Innovative SunLike LEDs Earn Industry Recognition in 2018 IES Progress Report13.8.2018 16:00 | Tiedote
Seoul Semiconductor (KOSDAQ 046890), a leading global innovator of LED products and technology, has announced that its SunLike Series natural spectrum LEDs, powered by TRI-R, were recognized in the 2018 Illumination Engineering Society (IES) Progress Report, presented on August 10, 2018 at the IES Annual Conference in Boston, MA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180813005229/en/ Seoul Semiconductor’s SunLike was recognized in the 2018 IES Progress Report (Graphic: Business Wire) As the recognized technical and educational authority on illumination, IES annually announces significant new advancements in lighting products, research, publications, and design tools in its IES Progress Report. Acceptance is based on an impartial judging process used by the committee to evaluate each submission on its uniqueness, innovation and significance to the lighting industry. SunLike Series natural spectrum LEDs are the world’
Skunkworks Surfing Co. Co-Founders Appointed to be Endowment for Clean Oceans Judges13.8.2018 14:07 | Tiedote
The Endowment for Clean Oceans (ECO) announced that Skunkworks Surfing Co. Co-Founders CEO Chris and Ricky Martin have been selected and they have accepted to be ECO judges. Chris will serve on the Science and Tech Committee, and Ricky on the Entrepreneur Committee. An entrepreneur’s survival depends on their ability to execute their technical vision. “They have the sort of innovative entrepreneur and plastic materials technical expertise we are looking for to be ECO judges,” said Daniel Perrin, Founder and CEO of ECO. The role of the Entrepreneur Committee is to judge each entry to ECO’s two contests for scalability and executability. The Scientific and Technical Committee evaluate each entry from that perspective. “We are extremely excited to be part of this important and historic work,” said the Martin brothers. ECO’s contests are simply to provide a $1 million prize for an actionable and scalable plan to remove the micro and macro pieces of plastic from the ocean, and for the $5 mi
Calvin Klein Fragrances Releases CALVIN KLEIN WOMEN Global Television Advertising Campaign Featuring Actors Lupita Nyong'o and Saoirse Ronan13.8.2018 14:00 | Tiedote
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today revealed the worldwide television advertising campaign for CALVIN KLEIN WOMEN, the first CALVIN KLEIN fragrance to be developed under the vision of Chief Creative Officer Raf Simons. The campaign features Lupita Nyong'o and Saoirse Ronan. Directed by artist Anne Collier with creative direction from Lloyd & Co., the television campaign unfolds into a series of vignettes that provide a glimpse into Lupita Nyong'o’s and Saoirse Ronan’s creative inspirations. An extension of the print campaign, the commercial follows both women as they reflect on and embrace figures from the past that have inspired them and shaped their identities as women. Viewers see Saoirse playing a Nina Simone record and sharing admiration for Sissy Spacek, while referencing her on the cover of a vintage magazine, while Lupita draws inspiration from beautiful collaged photogr
GN Hearing Announces Unprecedented Layers of Sound™ and the World’s Most Advanced Rechargeable Hearing Aid Solution13.8.2018 14:00 | Tiedote
GN Hearing today unveils the world’s first Premium-Plus hearing aid: ReSound LiNX Quattro™, designed for people who want the very best that technology has to offer and desire a brilliant sound experience with great speech intelligibility even in noisy situations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180813005254/en/ Unprecedented Layers of Sound™ and the World’s Most Advanced Rechargeable Hearing Aid Solution (Photo: Business Wire) ReSound LiNX Quattro™ offers a new category of hearing solution and expands GN Hearing’s product portfolio, which already includes the premium ReSound LiNX 3D™ product family. Powered by new technology, including a new chip platform, ReSound LiNX Quattro™ offers a combination of unmatched sound quality and rechargeability, while further expanding GN Hearing’s leadership within 2.4 GHz connectivity and remote fine-tuning: Sound quality: A brilliant sound experience, with clearer, fuller a
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme